(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
5 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 14.44%
@ $1.418
発行日: 15 2月 2024 @ 05:43
リターン: -25.25%
前回のシグナル: 2月 14 - 02:41
前回のシグナル:
リターン: 12.54 %
Live Chart Being Loaded With Signals
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases...
Stats | |
---|---|
本日の出来高 | 652 441 |
平均出来高 | 1.79M |
時価総額 | 123.45M |
EPS | $0 ( 2024-02-29 ) |
次の収益日 | ( $-0.330 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.850 |
ATR14 | $0.00200 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-22 | Rangwala Reshma | Sell | 6 789 | Common Stock |
2024-04-04 | Paulson Richard A. | Sell | 3 563 | Common Stock |
2024-03-05 | Paulson Richard A. | Sell | 3 573 | Common Stock |
2024-02-29 | Rangwala Reshma | Sell | 15 667 | Common |
2024-03-01 | Rangwala Reshma | Sell | 5 969 | Common |
INSIDER POWER |
---|
69.84 |
Last 99 transactions |
Buy: 2 857 011 | Sell: 554 783 |
ボリューム 相関
Karyopharm Therapeutics 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Karyopharm Therapeutics 相関 - 通貨/商品
Karyopharm Therapeutics 財務諸表
Annual | 2023 |
収益: | $146.03M |
総利益: | $140.56M (96.25 %) |
EPS: | $-1.250 |
FY | 2023 |
収益: | $146.03M |
総利益: | $140.56M (96.25 %) |
EPS: | $-1.250 |
FY | 2022 |
収益: | $157.07M |
総利益: | $151.86M (96.68 %) |
EPS: | $-2.02 |
FY | 2021 |
収益: | $209.82M |
総利益: | $206.42M (98.38 %) |
EPS: | $-1.650 |
Financial Reports:
No articles found.
Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。